International differences in treatment effects in cardiovascular clinical trials

American Heart Journal

Volumn 141, Issue 5, 2001, Pages 875-880

  O'Shea, J Conor ^a   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPTIFIBATIDE; FIBRINOLYTIC AGENT; HEPARIN; METOPROLOL; PLACEBO; PROSTACYCLIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035038714     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.115186     Document Type: Conference Paper

References (18)

1. Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: Variation by country beyond predictive profile
2. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
3. Inter-regional differences and outcome in unstable angina: Analysis of the international ESSENCE trial
4. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)
5. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
7. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure
8. Hemodynamic responses to prostacyclin (PGI2) in the conscious sheep
9. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
10. Results of the economic evaluation of the first study: A multinational prospective economic evaluation
11. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes: PURSUIT Investigators
12. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: Insights from the Platelet Glycoprorein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
13. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
14. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: Results from PURSUIT
15. Why do we need some large, simple randomized trials?
16. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting
17. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK
18. Platelet glycoprotein IIIa polymorphism and coronary thrombosis